Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Adam Eckert

Why BioXcel Therapeutics Stock Is Surging Today

BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

IGALMI is the first new acute treatment for schizophrenia or bipolar disorder-associated agitation in nearly a decade. It can be self-administrated by patients under the supervision of a healthcare provider. 

BioXcel said it expects to launch IGALMI in the U.S. in the second quarter.

BioXcel is a biopharmaceutical company utilizing artificial intelligence approaches to identify and develop transformative medicines in neuroscience and immuno-oncology.

See Also: Why Tilray Brands Stock Is Trading Higher Today

BTAI 52-Week Range: $14.32 - $38.99

The stock was up 16.9% at $23.16 at press time, according to data from Benzinga Pro.

Photo: jarmoluk from Pixabay.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.